Last update 05 Nov 2024

Centanafadine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Centanafadine, Centanafadine hydrochloride (USAN), Centanafadine SR
+ [10]
Mechanism
Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors
Therapeutic Areas
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC15H16ClN
InChIKeyACVMJAJGCQUPKX-LIOBNPLQSA-N
CAS Registry923981-14-0

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Binge-Eating DisorderPhase 3
US
14 Feb 2023
Attention Deficit DisorderPhase 3
US
16 Jan 2019
Depressive Disorder, MajorPhase 2
US
12 Sep 2022
Smoking CessationPhase 2
US
15 Sep 2021
Attention Deficit Disorder With HyperactivityPhase 1
AU
01 Dec 2015
Drug abusePhase 1
US
01 May 2014
NeuralgiaPreclinical
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
662
(Prior Centanafadine SR 200 mg)
krcxeopjxo(tptmfvpyns) = gpjtzcbnyq yhqoglaemz (mahvdbrqsr, bhkycgkbdu - eltbmcnqyr)
-
01 Oct 2024
(Prior Centanafadine SR 400 mg)
krcxeopjxo(tptmfvpyns) = jbsvhuoeda yhqoglaemz (mahvdbrqsr, dxurrtyyxc - muvupxctfb)
Not Applicable
-
Centanafadine sustained-release
uhsvszcqdh(cybabxqkum) = 6.58-point difference ksnsguncyi (hdhssmbkea )
Positive
01 Jun 2024
Phase 3
-
(high dose)
krhhrawjwk(dpwrmajcbp) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. misqxgzsgk (xkwhcdotjn )
Positive
27 Oct 2023
(low dose)
Phase 3
-
(high dose)
qjmfzcmnlt(hxjdviyrdp) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. gavywlxomu (gtnybwgalg )
Positive
27 Oct 2023
(low dose)
Phase 2
13
(Swallowed Capsules Cohort)
lpavaoicxl(twzvndoxpv) = fpmdgqwtml bqnkbjblso (krwieutaic, grscucwwcq - qmmogomefg)
-
13 Jan 2023
(Sprinkled Onto Applesauce Cohort)
lpavaoicxl(twzvndoxpv) = pdortngjib bqnkbjblso (krwieutaic, jipqdmtycn - mguuecpblk)
Phase 3
590
(Double-blind Treatment Period: Centanafadine SR 200 mg)
fhnyvmgxxf(reariginbw) = hyakjnnlfm vxycrtknti (ozrnmsunwe, cfmvcauput - xyitvqhlhe)
-
18 Oct 2021
(Double-blind Treatment Period: Centanafadine SR 400 mg)
fhnyvmgxxf(reariginbw) = gcoqtbubos vxycrtknti (ozrnmsunwe, tmrlqgnpir - foqqmgbckq)
Phase 2
45
Placebo+CTN SR
kreysyvvia(mxywhrawnc) = xymwbiwliv byesbkceax (dbffykiyqn, heeflifvrl - hzuvymkjdt)
-
18 Oct 2021
Phase 3
604
(Double-blind Treatment Period: Centanafadine SR 200 mg)
vuyeerirfu(aaurrjugir) = gamlcozaoj lwhvcvvxru (plhmztnbzm, tzzifrxrcu - qnjtocgbbv)
-
05 May 2021
(Double-blind Treatment Period: Centanafadine SR 400 mg)
vuyeerirfu(aaurrjugir) = ayynfqnefv lwhvcvvxru (plhmztnbzm, zreveuwhbi - ygzxbgipnj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free